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Botulinum toxin (BoNT), a potent neurotoxin that reversibly blocks presynaptic acetylcholine re-
lease, has been applied successfully to treat severe sleep bruxism (SB). However, little work has 
been reviewed on the effectiveness of BoNT and its injection protocol such as drug dose and injec-
tion sites in masticatory muscles. Therefore, we reviewed recent studies on application of BoNT in 
SB patients. Sleep Med Res 2018;9(2):73-76
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INTRODUCTION
Sleep bruxism (SB), a stereotyped oromandibular activity during sleep, is characterized by 
teeth grinding and clenching [1]. SB was classified in the revised version of the 2005 Interna-
tional Classification of Sleep Disorders as a “sleep-related movement disorder” [2]. Based on 
bed-partner reports of tooth grinding, SB occurs in 5–8% of the adult population. The preva-
lence of SB decreases from childhood at 14–20% to old age at 3%. No gender difference in SB 
prevalence has been noted [3].
The evolution of definition and classification of SB has allowed this entity to become more 
distinct and homogenous. Increased focus facilitates research activities, resulting in improved 
understanding of etiological factors and physiological processes associated with SB. Despite 
many recognized risk factors for SB, its etiology and pathophysiology are yet to be established. 
There is convincing evidence that bruxism is part of an arousal response and sleep-related 
movement disorder. In short, bruxism is mainly mediated centrally, not peripherally [4]. SB is 
no longer considered to be simply related to mechanistic factors such as occlusal discrepan-
cies or due to psychological issues such as stress, anxiety, depression, or a combination of them. 
SB is considered as primarily a sleep-related movement disorder with a yet to be discerned mul-
tifactorial etiology and complex multisystem physiological processes [5].
SB has many clinical symptoms, including a tooth-grinding noise that might be reported by 
bed partner, pain in the temporomandibular joint and masticatory muscles, headache (espe-
cially in the temporal zone when the patient wakes up in the morning), tooth hypersensitivity, 
and morning jaw stiffness. Some clinical signs include abnormal tooth wear, tongue indenta-
tion, linea alba, hypertrophy of masseter muscles, and breakage of fillings and/or teeth. How-
ever, many of the deleterious effects of SB are permanent; clinically speaking, it is sometimes 
difficult to ascertain [6].
MaNageMeNT Of Sleep BRUxISM
There are various treatment modalities for the management of SB, including occlusal appli-
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ances, behavioral approaches, and pharmacological manage-
ment. However, none of them has been reported to be able to 
treat SB perfectly [2]. Treatment of bruxism is indicated when 
the disorder causes any of these aforementioned problems. 
Treatment is designed primarily to prevent further damage to 
the teeth. Unfortunately, there is no evidence that bruxism can 
be permanently altered by dental, behavioral, or pharmacologi-
cal intervention. Clinician’s choice of management option is 
driven by the need to protect orofacial structures from damage 
and relieve any accompanying pain related to sensory com-
plaints. 
Occlusal approaches
Oral appliances may reduce bruxism, muscular activities, and 
myofascial pains. Oral appliances can generally prevent tooth 
wear and injury and perhaps reduce night time clenching or 
grinding behavior rather than altering a causative malocclusion. 
Although these appliances can help reduce muscle pain, they 
are unlikely to significantly reduce nocturnal behavior. These ap-
pliances are worn every night by bruxers (Fig. 1) [7]. They can 
protect dental surfaces and relax masticatory muscles. They have 
been extensively used in clinical practice. However, their exact 
mechanisms of action are still under debate. No evidence sup-
ports their role in stopping SB.
Behavioral approaches
Nocturnal alarms have been used to treat bruxism. Typically, 
these devices monitor masticatory electromyography (EMG) 
activity or sounds. When the activity exceeds a threshold for a 
given period of time, an alarm sounds and wakes the bruxer to 
terminate the grinding/clenching behaviors. Because sleep is 
disrupted, patients who use nocturnal alarms may report sleepi-
ness and difficulty in concentrating if an alarm is being used. 
Discontinuation of the alarm may lead to “Rebound” in the level 
of grinding.
pharmacologic approaches
The etiopathophysiology of SB is still unclear. However, con-
siderable evidence indicates that monoamine neurotransmit-
ters, especially dopamine, may play a role in the development of 
this disorder. A previous controlled study of dopamine precur-
sor L-dopa, and a recent case report involving dopamine D1/
D2 receptor agonist pergolide have demonstrated the effective 
use of dopaminergic agents for treatment of SB [8]. This sup-
ports the currently unproven hypothesis that dopamine deple-
tion causes this disorder [9]. However, inconsistent results have 
been reported for another D2 agonist, bromocriptine. Medica-
tions for the management of bruxism have been studied increas-
ingly over the last few years, including BoNT, anticonvulsant 
drugs, and selective serotonin reuptake inhibitor. Unfortunate-
ly, there is only limited evidence showing efficacy of any of these 
drugs. Most studies are case reports. Thus, no definite conclusions 
can be drawn. Despite studies have provided evidence that the 
dopaminergic system plays a crucial role in SB, the mechanism 
of psychotropic drug-induced bruxism is still poorly understood. 
Psychotropic drugs can also modulate other neurotransmitters. 
This may cause different and sometimes opposite effects on ei-
ther awake or SB [9].
The most recent advocated pharmacological approach to 
manage pathological effects of nocturnal and diurnal bruxism 
is by injecting muscles of mastication with BoNT. Recent re-
search studies have shown that BoNT is effective for control-
ling involuntary orofacial movements and secondary bruxism in 
patients with movement disorders (e.g., cranial dystonia) [10-
13]. However, most relevant studies are case reports. Very few 
systematic studies have provided high-quality data for the man-
agement of SB. Lee et al. [14] have studied the effect of BoNT 
on nocturnal bruxism using a portable EMG device and found 
that BoNT injection can reduce the number of nocturnal brux-
ism events for up to 12 weeks. However, these data were as-
sessed by automatic detections based on EMG threshold. This 
method has difficulty in discriminating between SB and other 
oral motor activities based on portable EMG. Although many 
studies have evaluated SB patients and normal non-bruxers us-
ing polysomnography (PSG) [15,16], only one study has used 
PSG to study the effect of BoNT on SB [17].
It is known that masseter and temporalis muscles are mus-
cles related to SB [17]. Many case studies have reported injec-
tions of the masseter muscle, while others have injected both 
masseter and temporal muscles [18-20]. Although many people 
might think that the temporal muscle plays a smaller role in SB, 
it is likely that temporal and masseter muscles are involved in 
SB equally. 
Only one study has evaluated the effect of a single BoNT in-
jection on SB using PSG [17]. Results of that study showed that 
Fig. 1. An occlusal view of oral appliance. Although this appliance 
can help reduce muscle pain, they do not always stop a patient 
from bruxing. This appliance is worn every night by bruxer.
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BoNT injection to masseter and temporalis muscles did not 
change the occurrence of rhythmic masticatory muscle activity 
(RMMA) episodes or orofacial activities. However, the ampli-
tude of EMG burst during RMMA episodes was significantly 
decreased for muscles that received BoNT injection. There were 
no significant differences in usual sleep variables such as sleep 
efficiency, arousal index, sleep stages, or awakenings per hour 
between baseline and follow-up recordings [17].
These findings confirmed that the effect of BoNT on jaw 
motor activity during sleep was characterized by a reduction in 
the intensity of contractions in injected muscles rather than by 
a reduction in event occurrence [21-24]. In that study, BoNT at 
a dose of 25 U was usually injected into each muscles using a 
1-mL-syringe with a 29-gauge, 0.5-inch needle. BoNT was in-
jected into two to three sites of each subject’s masseter and/or 
temporalis muscles. The method of injection into masseter 
muscle is the same as the injection for masseter muscle hyper-
trophy. In the temporalis muscle, the first site was the prominent 
part of the anterior temporalis muscle that was observed when 
the subject was asked to clench. It was parallel to the eyebrow. 
The other two sites were 10 mm and 20 mm posterior from the 
first site [17].
aNaTOMICal ReCOMMeNDaTIONS  
fOR Safe BOTUlINUM TOxIN 
INjeCTION INTO MaSSeTeR aND 
TeMpORalIS MUSCle
Masseter Muscle
The injection of the masseter muscle in SB patient use the 
same technique as that used for masseteric hypertrophy injec-
tion. Botulinum toxin injection sites (blue dots) are separated 
by 1 cm in the center of the middle third of the masseter mus-
cle. These two injection points are used for most females and 
for males with a narrow cheek, with 25 U of botulinum toxin 
being injected (Fig. 2).
Temporalis Muscle
Lee et al. [25] have performed a study to simplify optimal tem-
poral areas with a safe and reproducible approach for BoNT in-
jections into the temporalis muscle. They carried out detailed 
dissections and measurements of structures in the temporal 
area to virtually represent a topographic mapping of postural 
Fig. 2. Botulinum toxin injection sites (blue dots) separated by 
1 cm in the center of the middle third of the masseter muscle. 
These two injection points are used for most females and for 
males with a narrow cheek, with 25 U of botulinum toxin being in-
jected. PG: parotid gland, PD: parotid duct, M: masseter muscle, 
R: risorius muscle, FA: facial artery, FV: facial vein.
Fig. 4. Suggested temporal injection points for sleep bruxism. It is 
recommended to inject a total of 25 U of botulinum toxin into 
three points (red dots on fingertips) within the nine compartments 
of the temporal region.
Fig. 3. Lateral view of the neuromuscular partitions of the tempo-
ralis muscle. ADT: anterior deep temporal nerve, M: masseteric 
nerve, MDT: middle deep temporal nerve, PDT: posterior deep 
temporal nerve.
76  Sleep Med Res 2018;9(2):73-76
Botulinum Toxin Injection
relations among major anatomical structures, such as temporal 
branch of the facial nerve in the temporalis muscle of the tem-
poral area (Figs. 3 and 4).
They proposed safe and reproducible injection sites in the 
form of compartments. It would be helpful to further specify 
the exact position of the injection site within the nine temporalis 
muscle compartments described herein, to enable clinician to 
perform injections with greater confidence.
CONClUSION
SB and its consequences are complex. They require a com-
mitted personalized approach to change behaviors through oral 
appliances, behavioral approaches, and medications. The pri-
mary option for managing SB is still a full-arch oral appliance. 
For extreme cases, BoNT injections can be applied.
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